Delving into the Latest Updates on RV-1729 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

Mechanism

PI3Kγ inhibitors(Phosphatidylinositol 3 kinase gamma inhibitors), PI3Kδ inhibitors(Phosphatidylinositol 3 kinase delta inhibitors)

Therapeutic Areas

Immune System DiseasesRespiratory Diseases

Active Indication-

Inactive Indication

AsthmaPulmonary Disease, Chronic Obstructive

Originator Organization

RespiVert Ltd.

Active Organization-

Inactive Organization

RespiVert Ltd.

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC39H39ClN8O5

InChIKeyUBLOHCIYTDRGJH-UHFFFAOYSA-N

CAS Registry1293915-42-0

RV1729 is a new medicine being developed for the potential treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD). The objective of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics repeat doses of RV1729 in patients with COPD for 28 days.

Start Date01 Aug 2014

Sponsor / Collaborator

RespiVert Ltd.

NCT02140320 / CompletedPhase 1

A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treatment With Single and Repeat Doses of Inhaled RV1729 in Healthy Subjects for up to 28 Days and Subjects With Stable Asthma for 14 Days

RV1729 is a new medicine being developed for the potential treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD).
The objective of this study is to investigate the safety, tolerability and pharmacokinetics of single doses of RV1729 and repeat doses of RV1729 for up to 28 days.

Start Date01 Jul 2014

Sponsor / Collaborator

RespiVert Ltd.

NCT01813084 / CompletedPhase 1

A Randomised, Double Blind, Placebo-controlled, Three Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treatment With Single and Repeat Doses of Inhaled RV1729 in Healthy Subjects and Subjects With Mild to Moderate Asthma

RV1729 is a new medicine being developed for possible treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD).
The main purpose of this study is to investigate the safety, tolerability and pharmacokinetics of single and repeat doses of RV1729.

Start Date01 May 2013

Sponsor / Collaborator

RespiVert Ltd.

100 Clinical Results associated with RV-1729

Login to view more data

100 Translational Medicine associated with RV-1729

Login to view more data

100 Patents (Medical) associated with RV-1729

Login to view more data

100 Deals associated with RV-1729

Login to view more data